Item 7.01 Regulation FD Disclosure.

NGM Biopharmaceuticals, Inc. (the "Company") will be conducting meetings with securities analysts, investors and others in connection with the 38th Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 13, 2020. As part of these meetings, the Company intends to utilize the corporate slide presentation furnished with this report as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits





Exhibit No.                                  Description

99.1                NGM Biopharmaceuticals, Inc. Corporate Presentation, dated
                  January 13, 2020.

The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by NGM Biopharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses